Hubei Guangji Pharmaceutical Co., Ltd.

Primary objective: To evaluate the pharmacokinetic characteristics of ruxolitinib phosphate tablets (test preparation, specification: 5 mg; produced by Chongqing Boteng Pharmaceutical Co., Ltd.) produced by Hubei Guangji Pharmaceutical Technology Co., Ltd. and ruxolitinib phosphate tablets (reference preparation, specification: 5 mg, trade name: Jakavi) produced by Novartis Pharma Stein AG, Switzerland under the conditions of single fasting/fed administration (5 mg) in healthy Chinese subjects, and to evaluate the bioequivalence of the test preparation and the reference preparation. Secondary objective: To evaluate the safety of single administration of 5 mg test preparation ruxolitinib phosphate tablets and 5 mg reference preparation ruxolitinib phosphate tablets (Jakavi) under fasting and fed conditions in healthy Chinese subjects.

Primary study objective: This study uses tinidazole tablets (specification 0.5g) produced by Hubei Guangji Pharmaceutical Co., Ltd. and tinidazole tablets (trade name: TINDAMAX®, specification: 500mg/tablet) produced by Mission Pharmacal Company and licensed by Mikart inc Atlanta GA as reference preparations to evaluate the bioequivalence of the test preparation and the reference preparation when administered under postprandial conditions. Secondary study objective: To observe the safety of the test preparation and the reference preparation in healthy subjects.

Entecavir dispersible tablets provided by Hubei Guangji Pharmaceutical Co., Ltd. were used as the test preparation. According to the relevant regulations of the bioequivalence test, entecavir tablets (BARACLUDE ® ) produced by BRISTOLMYERS SQUIBB were used as the reference preparation to compare the relative bioavailability in healthy humans and investigate the human bioequivalence of the two preparations.